# Colon Neoadjuvant FOLFOXIRI Study

> **NCT01941641** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 40 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** neoadjuvant FOLFOXIRI
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01941641
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-10-09
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01941641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01941641, "Colon Neoadjuvant FOLFOXIRI Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01941641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*